The results from the expanded multi-centre validation study are positive, progressive and highly encouraging. The main data point to note is that the test continues to optimise with blood plasma biobank samples and linked electronic health record data, and improve its predictive power compared to the standard of care. In the high risk group, the positive predictive value (PPV) was 62% vs 41% for the KDIGO risk strata. This data builds on positive interims results previously announced in July 201 ....
10 Jun 2020
Further positive data to support KidneyIntelX’s FDA regulatory filing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Further positive data to support KidneyIntelX’s FDA regulatory filing
Renalytix Plc (RENX:LON) | 27.5 -0.1 (-1.8%) | Mkt Cap: 40.6m
- Published:
10 Jun 2020 -
Author:
Edward Thomason -
Pages:
4
The results from the expanded multi-centre validation study are positive, progressive and highly encouraging. The main data point to note is that the test continues to optimise with blood plasma biobank samples and linked electronic health record data, and improve its predictive power compared to the standard of care. In the high risk group, the positive predictive value (PPV) was 62% vs 41% for the KDIGO risk strata. This data builds on positive interims results previously announced in July 201 ....